Zymeworks Inc.
ZYME
Updated: 24/09/2026, 05:02:11
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
No summaries found.
- Share price
- $27.50
- Market cap
- $2.02B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Kenneth H. Galbraith
- Employees
- 231
- IPO date
- 28/04/2017
- Beta
- 1.191
- Last dividend
- $0.00
- Day range
- $26.54 – $27.89
- 52-week range
- $15.81 – $31.34
- 1-day performance
- -0.24%
- 1-year performance
- 73.94%
- Current drawdown (1Y)
- -12.25%
- CIK
- 0001937653
- CUSIP
- 98985Y108
- ISIN
- US98985Y1082
- Created
- 07/12/2025, 15:14:54
- Last update
- 24/09/2026, 05:02:11
Track Zymeworks Inc. with an AI analyst
See which prediction-market events move ZYME, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Globe News Wire • STOCK • 14/06/2026, 20:05:00
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
GlobeNewsWire • STOCK • 14/06/2026, 20:05:00
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
Seeking Alpha • STOCK • 22/05/2026, 09:30:00
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 13/05/2026, 08:00:00
Zymeworks Q1 Earnings Call Highlights
MarketBeat • STOCK • 09/05/2026, 07:07:36
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 09/05/2026, 02:21:17
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
GlobeNewsWire • STOCK • 21/04/2026, 19:30:00
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
GlobeNewsWire • STOCK • 17/04/2026, 17:00:00
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
GlobeNewsWire • STOCK • 16/04/2026, 08:00:00
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
GlobeNewsWire • STOCK • 09/04/2026, 08:00:00
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
GlobeNewsWire • STOCK • 01/04/2026, 08:00:00
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
GlobeNewsWire • STOCK • 30/03/2026, 08:00:00